{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:31:37Z","timestamp":1784835097576,"version":"3.55.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"DOI":"10.1007\/s11010-026-05534-w","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T09:34:47Z","timestamp":1778578487000},"page":"2429-2448","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Innovative valsartan-loaded self-nanoemulsifying drug delivery system combat liver inflammation and oxidative stress in streptozotocin-induced diabetic rats"],"prefix":"10.1007","volume":"481","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2585-9957","authenticated-orcid":false,"given":"Hanan","family":"Elimam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihan","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"El-Banna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zakaria","family":"El-Khayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Bakr","family":"Zaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami H.","family":"Alamri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek A.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid M.","family":"El-Say","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"issue":"1","key":"5534_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s42649-023-00089-2","volume":"53","author":"C-S Bae","year":"2023","unstructured":"Bae C-S, Lee Y, Ahn T (2023) Therapeutic treatments for diabetes mellitus-induced liver injury by regulating oxidative stress and inflammation. Appl Microscopy 53(1):4","journal-title":"Appl Microscopy"},{"key":"5534_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3389\/fphar.2020.00052","volume":"11","author":"Z Xu","year":"2020","unstructured":"Xu Z et al (2020) Fibroblast growth factor 1 ameliorates diabetes-induced liver injury by reducing cellular stress and restoring autophagy. Front Pharmacol 11:52","journal-title":"Front Pharmacol"},{"issue":"7","key":"5534_CR3","doi-asserted-by":"publisher","first-page":"e712","DOI":"10.1038\/cddis.2013.228","volume":"4","author":"T Kohl","year":"2013","unstructured":"Kohl T et al (2013) Diabetic liver injury from streptozotocin is regulated through the caspase-8 homolog cFLIP involving activation of JNK2 and intrahepatic immunocompetent cells. Cell Death Dis 4(7):e712\u2013e712","journal-title":"Cell Death Dis"},{"issue":"1","key":"5534_CR4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13098-022-00935-5","volume":"14","author":"AM Mahfoz","year":"2022","unstructured":"Mahfoz AM, Gawish AY (2022) Insight into the hepatoprotective, hypolipidemic, and antidiabetic impacts of aliskiren in streptozotocin-induced diabetic liver disease in mice. Diabetol Metab Syndr 14(1):163","journal-title":"Diabetol Metab Syndr"},{"issue":"4","key":"5534_CR5","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3390\/diseases11040184","volume":"11","author":"QH Alqahtani","year":"2023","unstructured":"Alqahtani QH et al (2023) Protective Effects of Sitagliptin on Streptozotocin-Induced Hepatic Injury in Diabetic Rats: A Possible Mechanisms. Diseases 11(4):184","journal-title":"Diseases"},{"key":"5534_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/08038020701832716","volume":"1","author":"J Tuomilehto","year":"2008","unstructured":"Tuomilehto J et al (2008) Combination therapy with valsartan\/hydrochlorothiazide at doses up to 320\/25\u00a0mg improves blood pressure levels in patients with hypertension inadequately controlled by valsartan 320\u00a0mg monotherapy. Blood Press Suppl 1:15\u201323","journal-title":"Blood Press Suppl"},{"issue":"7","key":"5534_CR7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/jhh.2009.90","volume":"24","author":"DH Zappe","year":"2010","unstructured":"Zappe DH et al (2010) Effectiveness of initiating treatment with valsartan\/hydrochlorothiazide in patients with stage-1 or stage-2 hypertension. J Hum Hypertens 24(7):483\u2013491","journal-title":"J Hum Hypertens"},{"issue":"1\u20133","key":"5534_CR8","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ejphar.2012.04.028","volume":"685","author":"G Qiang","year":"2012","unstructured":"Qiang G et al (2012) Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes. Eur J Pharmacol 685(1\u20133):156\u2013164","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"5534_CR9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.biopha.2004.02.001","volume":"58","author":"RN Gursoy","year":"2004","unstructured":"Gursoy RN, Benita S (2004) Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 58(3):173\u2013182","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"5534_CR10","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1208\/s12249-015-0388-8","volume":"17","author":"V Nekkanti","year":"2016","unstructured":"Nekkanti V, Wang Z, Betageri GV (2016) Pharmacokinetic evaluation of improved oral bioavailability of Valsartan: proliposomes versus self-nanoemulsifying drug delivery system. AAPS PharmSciTech 17(4):851\u2013862","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"5534_CR11","first-page":"261","volume":"51","author":"R Kamel","year":"2013","unstructured":"Kamel R, Basha M (2013) Preparation and in vitro evaluation of rutin nanostructured liquisolid delivery system. Bull Fac Pharm Cairo Univ 51(2):261\u2013272","journal-title":"Bull Fac Pharm Cairo Univ"},{"key":"5534_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ph15010068","author":"TA Ahmed","year":"2022","unstructured":"Ahmed TA et al (2022) Development of 3D-printed, liquisolid and directly compressed glimepiride tablets, loaded with black seed oil self-nanoemulsifying drug delivery system: in vitro and in vivo characterization. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph15010068","journal-title":"Pharmaceuticals (Basel)"},{"key":"5534_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12121187","author":"FO Alotaibi","year":"2020","unstructured":"Alotaibi FO et al (2020) Clinical pharmacokinetic evaluation of optimized liquisolid tablets as a potential therapy for male sexual dysfunction. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics12121187","journal-title":"Pharmaceutics"},{"issue":"9","key":"5534_CR14","doi-asserted-by":"publisher","first-page":"12321","DOI":"10.1007\/s00210-025-03993-4","volume":"398","author":"H Elimam","year":"2025","unstructured":"Elimam H et al (2025) Nanoformulation of valsartan-loaded tablet attenuates L-NAME-induced hypertension: role of Nrf2\/PPAR\u03b3\/AT1 signaling pathway. Naunyn Schmiedebergs Arch Pharmacol 398(9):12321\u201312341","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"5534_CR15","doi-asserted-by":"publisher","first-page":"122966","DOI":"10.1016\/j.ijpharm.2023.122966","volume":"639","author":"KM El-Say","year":"2023","unstructured":"El-Say KM et al (2023) Incorporating valsartan in sesame oil enriched self-nanoemulsifying system-loaded liquisolid tablets to improve its bioavailability. Int J Pharm 639:122966","journal-title":"Int J Pharm"},{"issue":"5","key":"5534_CR16","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/jcb.30238","volume":"123","author":"H Elimam","year":"2022","unstructured":"Elimam H et al (2022) Preclinical activity of fluvastatin-loaded self-nanoemulsifying delivery system against breast cancer models: Emphasis on apoptosis. J Cell Biochem 123(5):947\u2013963","journal-title":"J Cell Biochem"},{"key":"5534_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2018.04.015","author":"HM Aldawsari","year":"2018","unstructured":"Aldawsari HM et al (2018) Development of a fluvastatin-loaded self-nanoemulsifying system to maximize therapeutic efficacy in human colorectal carcinoma cells. J Drug Deliv Sci Technol. https:\/\/doi.org\/10.1016\/j.jddst.2018.04.015","journal-title":"J Drug Deliv Sci Technol"},{"key":"5534_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12249-020-01754-5","volume":"21","author":"KM El-Say","year":"2020","unstructured":"El-Say KM et al (2020) Enhancing the hypolipidemic effect of simvastatin in poloxamer-induced hyperlipidemic rats via liquisolid approach: pharmacokinetic and pharmacodynamic evaluation. AAPS PharmSciTech 21:1\u201314","journal-title":"AAPS PharmSciTech"},{"key":"5534_CR19","doi-asserted-by":"publisher","first-page":"124454","DOI":"10.1016\/j.ijpharm.2024.124454","volume":"661","author":"W Tharanon","year":"2024","unstructured":"Tharanon W et al (2024) A systematic comparison of four pharmacopoeial methods for measuring powder flowability. Int J Pharm 661:124454","journal-title":"Int J Pharm"},{"key":"5534_CR20","volume-title":"Liquisolid systems and methods of preparing same","author":"S Spireas","year":"2002","unstructured":"Spireas S (2002) Liquisolid systems and methods of preparing same. Google Patents, Mountain View"},{"key":"5534_CR21","doi-asserted-by":"publisher","first-page":"160","DOI":"10.5625\/lar.2016.32.3.160","volume":"32","author":"A Mostafavinia","year":"2016","unstructured":"Mostafavinia A et al (2016) The effects of dosage and the routes of administrations of streptozotocin and alloxan on induction rate of typel diabetes mellitus and mortality rate in rats. Lab Anim Res 32:160\u2013165","journal-title":"Lab Anim Res"},{"issue":"12","key":"5534_CR22","doi-asserted-by":"publisher","first-page":"17695","DOI":"10.1007\/s00210-025-04356-9","volume":"398","author":"H Elimam","year":"2025","unstructured":"Elimam H et al (2025) Carvedilol-loaded self-nanoemulsifying drug delivery system target diabetic nephropathy: preclinical evidence of antioxidant and antifibrotic effects. Naunyn Schmiedebergs Arch Pharmacol 398(12):17695\u201317709","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"10","key":"5534_CR23","doi-asserted-by":"publisher","first-page":"e0311404","DOI":"10.1371\/journal.pone.0311404","volume":"19","author":"AV Cybulsky","year":"2024","unstructured":"Cybulsky AV et al (2024) Genetic deletion of calcium-independent phospholipase A2gamma protects mice from diabetic nephropathy. PLoS ONE 19(10):e0311404","journal-title":"PLoS ONE"},{"issue":"3","key":"5534_CR24","first-page":"251","volume":"22","author":"HX Liu","year":"2019","unstructured":"Liu HX, Li J, Li QX (2019) Therapeutic effect of valsartan against doxorubicin-induced renal toxicity in rats. Iran J Basic Med Sci 22(3):251\u2013254","journal-title":"Iran J Basic Med Sci"},{"issue":"7","key":"5534_CR25","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1093\/ndt\/16.7.1343","volume":"16","author":"JL Wilkinson-Berka","year":"2001","unstructured":"Wilkinson-Berka JL et al (2001) Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat. Nephrol Dial Transpl 16(7):1343\u20131349","journal-title":"Nephrol Dial Transpl"},{"key":"5534_CR26","volume-title":"Theory and practice of histological techniques","author":"JD Bancroft","year":"2008","unstructured":"Bancroft JD, Gamble M (2008) Theory and practice of histological techniques. Elsevier, Amsterdam"},{"issue":"6","key":"5534_CR27","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/BF02653674","volume":"66","author":"A Schmedes","year":"1989","unstructured":"Schmedes A, H\u00f8lmer G (1989) A new thiobarbituric acid (TBA) method for determining free malondialdehyde (MDA) and hydroperoxides selectively as a measure of lipid peroxidation. J Am Oil Chem Soc 66(6):813\u2013817","journal-title":"J Am Oil Chem Soc"},{"issue":"1086","key":"5534_CR28","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1039\/an9669100553","volume":"91","author":"G Norwitz","year":"1966","unstructured":"Norwitz G (1966) A colorimetric method for the determination of oxides of nitrogen. Analyst 91(1086):553\u2013558","journal-title":"Analyst"},{"issue":"3","key":"5534_CR29","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1042\/bj0940705","volume":"94","author":"C Owens","year":"1965","unstructured":"Owens C, Belcher R (1965) A colorimetric micro-method for the determination of glutathione. Biochem J 94(3):705","journal-title":"Biochem J"},{"issue":"2","key":"5534_CR30","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/BF02535780","volume":"28","author":"RB Shireman","year":"1993","unstructured":"Shireman RB, Durieux J (1993) Microplate methods for determination of serum cholesterol, high density lipoprotein cholesterol, triglyceride and apolipoproteins. Lipids 28(2):151\u2013155","journal-title":"Lipids"},{"issue":"3","key":"5534_CR31","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/0009-8981(68)90041-7","volume":"22","author":"MJ Fletcher","year":"1968","unstructured":"Fletcher MJ (1968) A colorimetric method for estimating serum triglycerides. Clin Chim Acta 22(3):393\u2013397","journal-title":"Clin Chim Acta"},{"issue":"4","key":"5534_CR32","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/clinchem\/20.4.470","volume":"20","author":"CC Allain","year":"1974","unstructured":"Allain CC et al (1974) Enzymatic determination of total serum cholesterol. Clin Chem 20(4):470\u2013475","journal-title":"Clin Chem"},{"key":"5534_CR33","doi-asserted-by":"publisher","first-page":"1204905","DOI":"10.3389\/fphar.2023.1204905","volume":"14","author":"J Gauvin","year":"2023","unstructured":"Gauvin J et al (2023) A cyclic azapeptide ligand of the scavenger receptor CD36\/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice. Front Pharmacol 14:1204905","journal-title":"Front Pharmacol"},{"issue":"4","key":"5534_CR34","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3109\/00365516009065404","volume":"12","author":"BE Raabo","year":"1960","unstructured":"Raabo BE, Terkildsen T (1960) On the enzymatic determination of blood glucose. Scand J Clin Lab Investig 12(4):402\u2013407","journal-title":"Scand J Clin Lab Investig"},{"key":"5534_CR35","volume-title":"Methods of enzymatic analysis","author":"H-U Bergmeyer","year":"2012","unstructured":"Bergmeyer H-U (2012) Methods of enzymatic analysis. Elsevier, Amsterdam"},{"issue":"2","key":"5534_CR36","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.18295\/squmj.2016.16.02.002","volume":"16","author":"J Mohamed","year":"2016","unstructured":"Mohamed J et al (2016) Mechanisms of Diabetes-Induced Liver Damage: The role of oxidative stress and inflammation. Sultan Qaboos Univ Med J 16(2):e132\u2013e141","journal-title":"Sultan Qaboos Univ Med J"},{"issue":"6","key":"5534_CR37","doi-asserted-by":"publisher","first-page":"780","DOI":"10.5604\/16652681.1171746","volume":"14","author":"D Garc\u00eda-Compe\u00e1n","year":"2015","unstructured":"Garc\u00eda-Compe\u00e1n D et al (2015) The treatment of diabetes mellitus of patients with chronic liver disease. Ann Hepatol 14(6):780\u2013788","journal-title":"Ann Hepatol"},{"issue":"3","key":"5534_CR38","first-page":"45","volume":"11","author":"OO Oguntibeju","year":"2019","unstructured":"Oguntibeju OO (2019) Type 2 diabetes mellitus, oxidative stress and inflammation: examining the links. Int J Physiol Pathophysiol Pharmacol 11(3):45\u201363","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"key":"5534_CR39","first-page":"12","volume":"1","author":"N Siddiqui","year":"2011","unstructured":"Siddiqui N et al (2011) Pharmacological and pharmaceutical profile of valsartan: a review. J Appl Pharm Sci 1:12\u201319","journal-title":"J Appl Pharm Sci"},{"issue":"2","key":"5534_CR40","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.acthis.2006.03.005","volume":"108","author":"A Guven","year":"2006","unstructured":"Guven A et al (2006) Effects of melatonin on streptozotocin-induced diabetic liver injury in rats. Acta Histochem 108(2):85\u201393","journal-title":"Acta Histochem"},{"issue":"3","key":"5534_CR41","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1191\/0960327104ht507oa","volume":"24","author":"R Yanardag","year":"2005","unstructured":"Yanardag R et al (2005) Protective effects of metformin treatment on the liver injury of streptozotocin-diabetic rats. Hum Exp Toxicol 24(3):129\u2013135","journal-title":"Hum Exp Toxicol"},{"key":"5534_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/cells8111419","author":"B Dewidar","year":"2019","unstructured":"Dewidar B et al (2019) TGF-\u03b2 in hepatic stellate cell activation and liver fibrogenesis-updated 2019. Cells. https:\/\/doi.org\/10.3390\/cells8111419","journal-title":"Cells"},{"key":"5534_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.634902","author":"Q Yan","year":"2021","unstructured":"Yan Q et al (2021) RNF2 mediates hepatic stellate cells activation by regulating ERK\/p38 signaling pathway in LX-2 cells. Front Cell Dev Biol. https:\/\/doi.org\/10.3389\/fcell.2021.634902","journal-title":"Front Cell Dev Biol"},{"issue":"8","key":"5534_CR44","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1111\/jcmm.12551","volume":"19","author":"X Sui","year":"2015","unstructured":"Sui X, Wei H, Wang D (2015) Novel mechanism of cardiac protection by valsartan: synergetic roles of TGF-\u03b21 and HIF-1\u03b1 in Ang II-mediated fibrosis after myocardial infarction. J Cell Mol Med 19(8):1773\u20131782","journal-title":"J Cell Mol Med"},{"issue":"8","key":"5534_CR45","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1111\/j.1440-1746.2006.04331.x","volume":"21","author":"W Xu","year":"2006","unstructured":"Xu W et al (2006) Effects of perindopril and valsartan on expression of transforming growth factor-beta-Smads in experimental hepatic fibrosis in rats. J Gastroenterol Hepatol 21(8):1250\u20131256","journal-title":"J Gastroenterol Hepatol"},{"key":"5534_CR46","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13000-015-0246-8","volume":"10","author":"H Sun","year":"2015","unstructured":"Sun H et al (2015) Valsartan blocks thrombospondin\/transforming growth factor\/Smads to inhibit aortic remodeling in diabetic rats. Diagn Pathol 10:18","journal-title":"Diagn Pathol"},{"issue":"1","key":"5534_CR47","doi-asserted-by":"publisher","first-page":"13045","DOI":"10.1038\/s41598-020-69810-5","volume":"10","author":"GA Abdel-Latif","year":"2020","unstructured":"Abdel-Latif GA et al (2020) A novel protective role of sacubitril\/valsartan in cyclophosphamide induced lung injury in rats: impact of miRNA-150-3p on NF-\u03baB\/MAPK signaling trajectories. Sci Rep 10(1):13045","journal-title":"Sci Rep"},{"key":"5534_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1321095","author":"M Zhou","year":"2024","unstructured":"Zhou M et al (2024) Valsartan attenuates LPS-induced ALI by modulating NF-\u03baB and MAPK pathways. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2024.1321095","journal-title":"Front Pharmacol"},{"key":"5534_CR49","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.3389\/fphar.2018.01536","volume":"9","author":"L Staurengo-Ferrari","year":"2019","unstructured":"Staurengo-Ferrari L et al (2019) Contribution of Nrf2 modulation to the mechanism of action of analgesic and anti-inflammatory drugs in pre-clinical and clinical stages. Front Pharmacol 9:1536","journal-title":"Front Pharmacol"},{"issue":"8b","key":"5534_CR50","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1111\/j.1582-4934.2009.00874.x","volume":"13","author":"AT Churchman","year":"2009","unstructured":"Churchman AT et al (2009) Transforming growth factor-\u03b21 elicits Nrf2-mediated antioxidant responses in aortic smooth muscle cells. J Cell Mol Med 13(8b):2282\u20132292","journal-title":"J Cell Mol Med"},{"issue":"1","key":"5534_CR51","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3892\/mmr.2021.12138","volume":"24","author":"H Wang","year":"2021","unstructured":"Wang H et al (2021) Transforming growth factor\u2013\u03b21 functions as a competitive endogenous RNA that ameliorates intracranial hemorrhage injury by sponging microRNA\u201393\u20135p. Mol Med Rep 24(1):499","journal-title":"Mol Med Rep"},{"issue":"4","key":"5534_CR52","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1097\/00004872-200304000-00020","volume":"21","author":"P Chan","year":"2003","unstructured":"Chan P et al (2003) Antihyperglycemic action of angiotensin II receptor antagonist, valsartan, in streptozotocin-induced diabetic rats. J Hypertens 21(4):761\u2013769","journal-title":"J Hypertens"},{"issue":"18","key":"5534_CR53","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.7150\/ijms.49373","volume":"17","author":"F Alqahtani","year":"2020","unstructured":"Alqahtani F et al (2020) Angiotensin II receptor Neprilysin inhibitor (LCZ696) compared to Valsartan attenuates Hepatotoxicity in STZ-induced hyperglycemic rats. Int J Med Sci 17(18):3098","journal-title":"Int J Med Sci"},{"issue":"1","key":"5534_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1160","volume":"12","author":"WD Xu","year":"2024","unstructured":"Xu WD et al (2024) The blockade of the TGF-\u03b2 pathway alleviates abnormal glucose and lipid metabolism of lipodystrophy not obesity. Pharmacol Res Perspect 12(1):e1160","journal-title":"Pharmacol Res Perspect"},{"issue":"2","key":"5534_CR55","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.taap.2013.09.004","volume":"273","author":"S Siddiqui","year":"2013","unstructured":"Siddiqui S et al (2013) Protective effects of tocotrienols against lipid-induced nephropathy in experimental type-2 diabetic rats by modulation in TGF-\u03b2 expression. Toxicol Appl Pharmcol 273(2):314\u2013324","journal-title":"Toxicol Appl Pharmcol"},{"key":"5534_CR56","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.biopha.2017.05.103","volume":"92","author":"AA El-Kholy","year":"2017","unstructured":"El-Kholy AA, Elkablawy MA, El-Agamy DS (2017) Lutein mitigates cyclophosphamide induced lung and liver injury via NF-\u03baB\/MAPK dependent mechanism. Biomed Pharmacother 92:519\u2013527","journal-title":"Biomed Pharmacother"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05534-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-026-05534-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05534-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:03:23Z","timestamp":1781777003000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-026-05534-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":56,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["5534"],"URL":"https:\/\/doi.org\/10.1007\/s11010-026-05534-w","relation":{},"ISSN":["1573-4919"],"issn-type":[{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"20 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of University of Sadat City\u2019s ethics committee. Aproval was granted with protocol # RERC-FOP-USC-24-02-04 and all procedures complied with the ethical care criteria.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}